Gene:
KNG1
kininogen 1

PharmGKB contains no dosing guidelines for this . To report known genotype-based dosing guidelines, or if you are interested in developing guidelines, click here.

PharmGKB has no annotated drug labels with pharmacogenomic information for this . If you know of a drug label with PGx, send us a message.

PharmGKB contains no Clinical Variants that meet the highest level of criteria.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

Overview

Alternate Names:  BDK; KNG; alpha-2-thiol proteinase inhibitor; bradykinin
Alternate Symbols:  BK
PharmGKB Accession Id: PA225

Details

Cytogenetic Location: chr3 : q27.3 - q27.3
GP mRNA Boundary: chr3 : 186435098 - 186462199
GP Gene Boundary: chr3 : 186425098 - 186465199
Strand: plus

Visualization

UCSC has a Genome Browser that you can use to view PharmGKB annotations for this gene in context with many other sources of information.

View on UCSC Browser
The mRNA boundaries are calculated using the gene's default feature set from NCBI, mapped onto the UCSC Golden Path. PharmGKB sets gene boundaries by expanding the mRNA boundaries by no less than 10,000 bases upstream (5') and 3,000 bases downstream (3') to allow for potential regulatory regions.

Curated Information ?

Evidence Gene
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available PW
ACE

Curated Information ?

Curated Information ?

Publications related to KNG1: 6

No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Tailored therapy of ACE inhibitors in stable coronary artery disease: pharmacogenetic profiling of treatment benefit. Pharmacogenomics. 2010. Brugts Jasper J, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Common variants of large effect in F12, KNG1, and HRG are associated with activated partial thromboplastin time. American journal of human genetics. 2010. Houlihan Lorna M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Kininogen gene (KNG) variation has a consistent effect on aldosterone response to antihypertensive drug therapy: the GERA study. Physiological genomics. 2009. Barbalic Maja, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The rationale and design of the PERindopril GENEtic association study (PERGENE): a pharmacogenetic analysis of angiotensin-converting enzyme inhibitor therapy in patients with stable coronary artery disease. Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy. 2009. Brugts J J, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Angiotensin-converting enzyme inhibitor-associated angioedema is characterized by a slower degradation of des-arginine(9)-bradykinin. The Journal of pharmacology and experimental therapeutics. 2002. Molinaro Giuseppe, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Bradykinin-induced vasodilation of human coronary arteries in vivo: role of nitric oxide and angiotensin-converting enzyme. Journal of the American College of Cardiology. 1997. Kuga T, et al. PubMed

LinkOuts

NCBI Gene:
3827
OMIM:
228960
612358
UCSC Genome Browser:
NM_000893
RefSeq RNA:
NM_000893
NM_001102416
NM_001166451
RefSeq Protein:
NP_000884
NP_001095886
NP_001159923
RefSeq DNA:
NG_016009
NT_005612
UniProtKB:
C9JEX1_HUMAN (C9JEX1)
KNG1_HUMAN (P01042)
Ensembl:
ENSG00000113889
GenAtlas:
KNG1
GeneCard:
KNG1
MutDB:
KNG1
ALFRED:
LO075496F
HuGE:
KNG1
Comparative Toxicogenomics Database:
3827
ModBase:
P01042
HumanCyc Gene:
HS03725
HGNC:
6383

Common Searches